19-Oct-2026 - Yahoo Finance Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the ...
19-Oct-2026 - Yahoo Finance Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger. That sounds like an easy valuation story until the ...
19-Oct-2026 - The Globe and Mail Pfizer (PFE) Gets a Hold from Wells Fargo In a report released on October 16, Derek Archila from Wells Fargo maintained a Hold rating on Pfizer, with a price target of $28.00. The company’s shares closed last Friday at $29.58. According to ...
17-Oct-2026 - The Globe and Mail RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE) In a report released yesterday, Trung Huynh from RBC Capital maintained a Hold rating on Pfizer, with a price target of $25.00. Huynh covers the Healthcare sector, focusing on stocks such as ...
19-Oct-2026 - Yahoo Finance Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the ...
19-Oct-2026 - Yahoo Finance Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger. That sounds like an easy valuation story until the ...
19-Oct-2026 - The Globe and Mail Pfizer (PFE) Gets a Hold from Wells Fargo In a report released on October 16, Derek Archila from Wells Fargo maintained a Hold rating on Pfizer, with a price target of $28.00. The company’s shares closed last Friday at $29.58. According to ...
17-Oct-2026 - The Globe and Mail RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE) In a report released yesterday, Trung Huynh from RBC Capital maintained a Hold rating on Pfizer, with a price target of $25.00. Huynh covers the Healthcare sector, focusing on stocks such as ...
